To those who say “impossible, impractical, unrealistic,” we say:

CHALLENGE ACCEPTED

We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.

To those who say “impossible, impractical, unrealistic,” we say:

CHALLENGE ACCEPTED

We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.

AT THE FOREFRONT OF CHANGE

Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development.

>700
Employees
8
Programmes Currently in Clinical Development
>1k
Study Participants Dosed
>14k
Doses Administered
>20
Clinical Studies to Date
>3
Years Longest Duration of Exposure
_
_
_
_
_
_

*updated as of September 2017

RNAi: A REVOLUTION IN BIOLOGY BUILT ON Nobel Prize-Winning Research

RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.

Learn more

Our Focus

Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 3 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.

Therapeutic product candidates in late-stage (Phase 2 – Phase 3) development focus on hereditary ATTR (hATTR) amyloidosis, acute hepatic porphyrias, haemophilia and rare bleeding disorders, hypercholesterolaemia and complement-mediated diseases. We have a number of early-stage programmes in development.

See our pipeline
join our team

Join our Team

As we pursue our goal of becoming a commercial organization that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.

View current job openings boston globe awards

Contact Us

For inquiries or to request additional information, we can be reached by email or by calling the Alnylam Great Britain office.

Alnylam UK Ltd.

Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA

info@alnylam.co.uk

For investor relations, business development, media, and clinical trial information, please visit our global site

Learn More About Alnylam

In-depth information about our science, our pipeline, resources for medical professionals and patients, and the latest news about Alnylam.